Wealth Enhancement Advisory Services LLC Acquires New Shares in Sarepta Therapeutics, Inc. $SRPT

Wealth Enhancement Advisory Services LLC acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 43,778 shares of the biotechnology company’s stock, valued at approximately $844,000.

Other institutional investors also recently bought and sold shares of the company. State of Michigan Retirement System lifted its position in shares of Sarepta Therapeutics by 3.1% in the second quarter. State of Michigan Retirement System now owns 23,600 shares of the biotechnology company’s stock worth $404,000 after buying an additional 700 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Sarepta Therapeutics by 3.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 23,140 shares of the biotechnology company’s stock valued at $396,000 after acquiring an additional 744 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Sarepta Therapeutics by 25.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,042 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 819 shares during the last quarter. New York Life Investment Management LLC boosted its position in Sarepta Therapeutics by 10.0% during the second quarter. New York Life Investment Management LLC now owns 10,623 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 966 shares during the period. Finally, Nordea Investment Management AB grew its holdings in Sarepta Therapeutics by 1.6% during the second quarter. Nordea Investment Management AB now owns 69,363 shares of the biotechnology company’s stock valued at $1,185,000 after purchasing an additional 1,066 shares during the last quarter. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Stock Down 2.1%

SRPT stock opened at $20.28 on Wednesday. The business’s 50-day simple moving average is $21.62 and its 200 day simple moving average is $19.94. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. The company has a market cap of $2.13 billion, a PE ratio of -6.74, a price-to-earnings-growth ratio of 0.52 and a beta of 0.39. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $120.05.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Monday, November 3rd. The biotechnology company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.15). The firm had revenue of $399.36 million during the quarter, compared to the consensus estimate of $331.51 million. Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.Sarepta Therapeutics’s revenue was down 14.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.62 EPS. On average, research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Ian Michael Estepan sold 13,187 shares of the firm’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the completion of the transaction, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at $4,312,523. This trade represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 7.60% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on SRPT shares. Wall Street Zen cut shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Robert W. Baird dropped their target price on shares of Sarepta Therapeutics from $21.00 to $15.00 and set a “neutral” rating on the stock in a report on Tuesday, November 4th. Piper Sandler upped their price target on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a report on Thursday, October 30th. Royal Bank Of Canada raised their price target on Sarepta Therapeutics from $16.00 to $18.00 and gave the company a “sector perform” rating in a research report on Thursday, January 8th. Finally, Wedbush boosted their price objective on Sarepta Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research report on Friday, January 23rd. Nine equities research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Hold” and a consensus target price of $33.84.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.